ArticleDiscover oncology2025
MISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlobally, lung cancer is a malignant tumor with the highest morbidity and mortality rate, of which lung adenocarcinoma (LUAD) is the most common pathological type, accounting for about 40% of all cases. This study aims to investigate the impact and molecular mechanisms of mitotic spindle positioning (MISP) on the occurrence and progression of LUAD.
methodsThe expression level of MISP were evaluated by qPCR and Western blotting. Hippo signaling-related protein levels were measured by Western blotting. Co-immunoprecipitation assay was applied to assess the interaction between MISP and MST1. The roles of MISP in LUAD cells were determined through CCK-8 assay, transwell migration/invasion assay, and flow cytometric analysis. A xenograft tumor model (n = 6) was established to calculate the effect of MISP in vivo.
resultsMISP expression was significantly higher in LUAD tissues compared to normal tissues. MISP overexpression promoted LUAD cell proliferation and migration in in vitro models, as well as tumor growth and metastasis in LUAD animal models. Western blotting demonstrated that MISP overexpression increased the expression of YAP, TAZ and CYR61, and decreased the expression of MST1 and phosphorylated YAP, thereby blocking the Hippo signaling pathway. While MISP knockdown had the opposite effect. Mechanistic experiments revealed that MISP directly interacts with MST1, thereby inhibiting Hippo signaling.
conclusionsIn conclusion, our study reveals a novel discovery that MISP promotes the growth and invasion of LUAD cells by interacting with MST1 and suppressing the Hippo pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.